Baseline HbA1c was cardiovascular risk reduction was not different with semaglutide versus placebo; for all end points, except all-cause mortality, the risk reduction was similar. Across subgroups of HbA1c change, cardiovascular outcomes were also consistent. "We showed that even people with completely normal blood sugar have the same benefits in reducing MACEs as people with blood sugar levels in the prediabetes range," Lingvay said in a statement. "This is very important information that helps us understand which patients might benefit from the cardiovascular risk-lowering effects of this medicine."
Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.